2017 Fiscal Year Final Research Report
Study of the molecular mechanisms of novel therapeutic candidate for cytomegalovirus infection
| Project/Area Number |
15K09587
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Infectious disease medicine
|
|---|
| Research Institution | Hokuriku University |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
定成 秀貴 北陸大学, 薬学部, 講師 (60121274)
|
|---|
| Co-Investigator(Renkei-kenkyūsha) |
EIZURU Yoshito 鹿児島大学, 医学部, 名誉教授 (00041351)
|
|---|
| Project Period (FY) |
2015-04-01 – 2018-03-31
|
| Keywords | ヒトサイトメガロウイルス / トリシン / ケモカイン / 抗ウイルス薬 |
|---|
| Outline of Final Research Achievements |
As a result of examining the molecular action mechanism of a novel therapeutic candidate "tricin" against human cytomegalovirus (HCMV), it was revealed that the action mechanism through the host chemokines molecule exists (Antiviral Res. 148, 15-19). In addition, from the study of the molecular mechanism of tricin suppression of HCMV gene expression, tricin inhibits the activity of RNA pol II by inhibiting the kinase activity of CDK9, and as a result, the molecular mechanism that suppresses the transcriptional activity of HCMV gene is obvious (FEBS Open Bio. 8, 646-654). Furthermore, by searching for a compound having more potent anti-HCMV activity than tricin, a compound having about 400 times more potent activity than tricin was synthesized by adding fluorine to tricin (Antiviral Res. 154, 10-16).
|
| Free Research Field |
ウイルス学、免疫学
|
